2.3 Chromatin Organization, Histone Modifications & DNA Methylation

2.3 Chromatin Organization, Histone Modifications & DNA Methylation

Quick Answer: In eukaryotic nuclei, ~2 meters of linear genomic DNA is packaged into chromatin via nucleosomes—octamers of basic core histones (two each of H2A, H2B, H3, H4) wrapped by 146–147 bp of DNA. Chromatin exists in a dynamic equilibrium between transcriptionally active, open euchromatin and silent, condensed heterochromatin. Epigenetic regulation is governed by post-translational histone modifications (acetylation by HATs opens chromatin; deacetylation by HDACs condenses chromatin) and covalent DNA methylation of CpG dinucleotides by DNA methyltransferases (DNMT1, DNMT3A/3B). In clinical diagnostics, sodium bisulfite conversion deaminates unmethylated cytosines to uracil (amplified as thymine) while leaving 5-methylcytosines intact, enabling methylation-specific PCR (MSP) for tumor suppressor silencing (MGMT, MLH1) and imprinting disorders (Prader-Willi and Angelman syndromes).

---

1. Nucleosome Architecture & Chromatin Compaction Hierarchy

If stretched linearly, the diploid human genome contains approximately 6 billion base pairs measuring ~2 meters in total length, all of which must be organized and condensed to fit inside a nuclear volume of only 5 to 10 $\mu\text{m}$ in diameter. This extraordinary degree of compaction is achieved without entangling or permanently inactivating the genome through structured association with specialized nuclear proteins called histones, forming the nucleoprotein complex known as chromatin.

    Nucleosome Core Particle:
        +-----------------------------------+
        |       Histone Octamer Core        |
        |   [ H2A-H2B ]     [ H2A-H2B ]     |  <-- Basic proteins rich in Lys & Arg
        |   [  H3-H4  ]     [  H3-H4  ]     |      (Net positive formal charge)
        +-----------------------------------+
             \                             /
              \--- 146-147 bp DNA Wrapped-/    <-- Polyanionic phosphate backbone
                   (1.65 Left-Handed Turns)        (Net negative formal charge)
                               |
                        [ Histone H1 ]         <-- Linker Histone (seals entry/exit)

The Nucleosome Core Particle

The fundamental, repeating structural subunit of eukaryotic chromatin is the nucleosome:

• The Core Histone Octamer: Consists of two copies of each of the four core histone proteins: $(H2A)_2, (H2B)_2, (H3)_2, (H4)_2$. Assembly proceeds via the formation of an $(H3-H4)_2$ tetramer, which is subsequently flanked by two $H2A-H2B$ heterodimers.
• DNA Wrapping: Exactly 146 to 147 base pairs (bp) of double-stranded DNA wraps around the histone octamer core in 1.65 left-handed superhelical turns.
• Chemical Bonding & Salt Bridges: Histones are highly basic proteins enriched with positively charged amino acids—predominantly Lysine (Lys, K) and Arginine (Arg, R). The positively charged $\epsilon$-amino groups of lysine and guanidino groups of arginine form tight non-covalent electrostatic salt bridges with the negatively charged polyanionic phosphodiester backbone of the DNA. This binding is structural and sequence-independent.
• Linker DNA and Histone H1: Adjacent nucleosomes are separated by a stretch of variable-length linker DNA (20–80 bp). The linker histone H1 binds to the exterior of the nucleosome at the DNA entry and exit sites, clamping the DNA in place and facilitating higher-order compaction. Digestion of chromatin with micrococcal nuclease (MNase) cleaves linker DNA first, releasing discrete ~200 bp "beads-on-a-string" nucleosomal fragments.

Hierarchical Levels of Chromatin Compaction

1. 10-nm Fiber ("Beads-on-a-String"): Uncondensed nucleosome chain with a diameter of ~10 nm; visible under electron microscopy at low ionic strength.
2. 30-nm Chromatin Fiber: Nucleosomes condense into a compact solenoid or zigzag helical array with a diameter of 30 nm, stabilized by linker histone H1 interactions and core histone N-terminal tail contacts.
3. 300-nm Looped Domains: The 30-nm fibers are organized into large looped domains (50–100 kb) anchored to a non-histone proteinaceous nuclear matrix / chromosome scaffold via specialized AT-rich sequences termed Scaffold/Matrix Attachment Regions (SARs/MARs), mediated by topoisomerase II$\alpha$ and condensin complexes.
4. 700-nm Condensed Chromatid: Looped domains condense further during prophase.
5. 1400-nm Metaphase Chromosome: The maximal level of chromatin compaction (~10,000-fold linear compaction) attained during metaphase of mitosis, enabling faithful segregation of sister chromatids without mechanical shearing.

---

2. Euchromatin vs. Heterochromatin: Structural & Functional Dynamics

Interphase chromatin is partitioned into two cytologically and functionally distinct compartments:

Subtypes of Heterochromatin

• Constitutive Heterochromatin: Chromatin regions that remain permanently condensed and transcriptionally inactive in all cell types throughout all stages of development. Characterized by tandemly repeated satellite DNA, high DNA methylation, and H3K9me3 marks bound by Heterochromatin Protein 1 (HP1). Prominent at centromeres, telomeres, and pericentromeric regions.
• Facultative Heterochromatin: Chromatin that is specifically silenced in certain cell lineages or developmental stages but retains the capacity to decondense and become transcriptionally active in others. Governed by H3K27me3 marks catalyzed by Polycomb Repressive Complex 2 (PRC2). The classic example is the inactive X chromosome (Barr body) in female mammalian somatic cells, initiated by the non-coding XIST RNA transcript coating the chromosome.

---

3. The Histone Code: Acetylation, Methylation & Enzymatic Regulators

The core histone proteins possess flexible, unstructured N-terminal tails that protrude outward from the nucleosome core through the DNA gyres. These tails undergo a diverse array of reversible post-translational modifications (PTMs)—including acetylation, methylation, phosphorylation, and ubiquitination—establishing the functional "Histone Code":

           +-------------------------------------------------------------+
           |                 The "Histone Code" Engine                   |
           |                                                             |
           |  "Writers" (Add Marks)   --->  "Readers" (Dock to Marks)     |
           |  - HATs (Acetylation)          - Bromodomains (Bind Ac-Lys) |
           |  - HMTs (Methylation)          - Chromodomains (Bind Me-Lys)|
           |  - Kinases (Phosphorylation)   - PHD Fingers                |
           |                                                             |
           |  "Erasers" (Remove Marks)                                   |
           |  - HDACs (Deacetylation)                                    |
           |  - KDMs (Demethylation)                                     |
           |  - Phosphatases                                             |
           +-------------------------------------------------------------+

Histone Acetylation vs. Deacetylation

• Histone Acetyltransferases (HATs / Writers): Catalyze the transfer of an acetyl group from acetyl-CoA to the $\epsilon$-amino group of specific lysine residues on histone tails (e.g., H3K9ac, H3K14ac, H3K27ac). Neutralizing the positive charge on lysine eliminates the electrostatic attraction to the polyanionic DNA backbone, allowing chromatin to decondense into an open euchromatin state accessible to basal transcription machinery (RNA Pol II) $\rightarrow$ Transcriptional Activation.
• Histone Deacetylases (HDACs / Erasers): Remove acetyl groups from lysine residues, restoring their positive formal charge. The positive lysine residues re-establish tight electrostatic salt bridges with the DNA backbone, compacting chromatin into a closed heterochromatin state $\rightarrow$ Transcriptional Repression.
• Clinical Therapeutics: HDAC inhibitors (e.g., Vorinostat [SAHA], Romidepsin) prevent deacetylation, sustaining histone hyperacetylation and re-inducing the expression of silenced tumor suppressor genes in cutaneous and peripheral T-cell lymphomas.

Histone Methylation

Unlike acetylation, histone methylation does not alter the electrical charge of the amino acid residue. Instead, mono-, di-, or tri-methyl groups added to lysine (K) or arginine (R) residues create specific hydrophobic docking sites for "reader" proteins:

---

4. DNA Methylation Machinery: CpG Islands, DNMTs, and Spontaneous Deamination

In human somatic cells, covalent DNA methylation occurs almost exclusively at the carbon-5 position of cytosine residues situated within symmetrical 5'-CpG-3' dinucleotides (cytosine followed by guanine separated by a single phosphate), yielding 5-methylcytosine ($5\text{-mC}$).

       Cytosine                             5-Methylcytosine (5-mC)
          NH2                                        NH2
        /     \                                    /     \
       N3      C4                                 N3      C4
      //        \                                //        \
     O=C2        C5-H      + SAM (DNMT)  --->   O=C2        C5-CH3 (Methyl Group!)
        \       /                                  \       /
         N1---CH                                    N1---CH
          | (1' Deoxyribose)                         | (1' Deoxyribose)

CpG Islands & Methylation Landscape

• CpG Islands (CGIs): Genomic regions of $\ge 200\text{ bp}$ with a GC content $>50%$ and an observed-to-expected CpG ratio $>0.6$. CGIs are situated within the promoters and 5' regulatory regions of approximately 60% to 70% of all human genes.
• Normal Somatic Methylation Pattern: In healthy differentiated somatic tissues:
  • Promoter CpG islands are kept UNMETHYLATED (hypomethylated), maintaining an open chromatin configuration that permits constitutive or inducible gene transcription.
  • Intergenic, repetitive, and retrotransposon sequences (e.g., LINE-1 elements, Alu repeats, satellite DNA) are HEAVILY METHYLATED (hypermethylated) to suppress illegitimate recombination and silence parasitic transposable elements.

Enzymatic Machinery: Maintenance vs. De Novo Methylation

• DNMT1 (Maintenance Methyltransferase): Shows a profound (~30- to 100-fold) biochemical preference for hemi-methylated DNA substrates (DNA where only the parental template strand is methylated following S-phase replication). DNMT1 associates with the replication fork via PCNA to copy methylation patterns faithfully onto the newly synthesized nascent daughter strand.
• DNMT3A and DNMT3B (De Novo Methyltransferases): Methylate previously unmethylated CpG dinucleotides independently of replication, establishing novel methylation marks during early embryonic development, gametogenesis, and cellular differentiation. Somatic mutations in DNMT3A (e.g., p.R882H) are frequent driver events in acute myeloid leukemia (AML) and clonal hematopoiesis of indeterminate potential (CHIP).
• TET Dioxygenases & Active Demethylation: Ten-Eleven Translocation (TET1, TET2, TET3) enzymes use oxygen and $\alpha$-ketoglutarate to iteratively oxidize 5-mC to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC). These oxidized bases are recognized and excised by Thymine DNA Glycosylase (TDG) and replaced with unmethylated cytosine via base excision repair (BER).

Mutational Vulnerability: The C-to-T Transition Hotspot

A critical clinical and evolutionary consequence of DNA methylation is spontaneous hydrolytic deamination:

• Deamination of Unmethylated Cytosine: Yields Uracil. Because uracil is foreign to DNA, it is immediately recognized and excised by Uracil-DNA Glycosylase (UDG), restoring wild-type cytosine with nearly 100% fidelity.
• Deamination of 5-Methylcytosine: Yields Thymine! This generates a $T:G$ mismatch. Because thymine is a natural constituent of DNA, cellular mismatch repair enzymes fail to consistently distinguish the mutated strand, frequently leading to permanent $C \rightarrow T$ transition mutations (and $G \rightarrow A$ on the reverse strand). Consequently, methylated CpG dinucleotides represent the single most common mutational hotspots in human genetic diseases and cancer genomes (e.g., TP53 hotspot mutations).

---

5. Clinical Epigenetics: Imprinting Syndromes, Cancer Biomarkers & Bisulfite Conversion

Epigenetic dysregulation plays a central role in human pathobiology and serves as an indispensable source of clinical diagnostic biomarkers.

Genomic Imprinting & Clinical Disorders

Genomic Imprinting is an epigenetic phenomenon in which a gene is expressed in a parent-of-origin-specific manner, mediated by differential DNA methylation of Imprinting Control Regions (ICRs) during gametogenesis:

• Prader-Willi Syndrome (PWS): Caused by loss of expression of normally paternally expressed genes on chromosome 15q11.2-q13 (e.g., SNRPN, MAGEL2, NDN). Mechanisms include paternal 15q11-q13 microdeletion (~70%), maternal uniparental disomy [UPD(15)mat] (~25%), or imprinting defects (~5%). Clinical phenotype: neonatal hypotonia, failure to thrive in infancy followed by hyperphagia, morbid obesity, intellectual disability, and hypogonadism.
• Angelman Syndrome (AS): Caused by loss of expression of the normally maternally expressed gene UBE3A on chromosome 15q11.2-q13. Mechanisms include maternal 15q11-q13 microdeletion (~70%), paternal uniparental disomy [UPD(15)pat] (~3–5%), UBE3A pathogenic sequence mutations (~10%), or imprinting defects. Clinical phenotype: severe intellectual disability, microcephaly, ataxia ("puppet-like" gait), seizures, and inappropriate unprovoked laughter.
• Methylation-Specific PCR (MS-PCR) or Methylation-Sensitive MLPA (MS-MLPA) targeting the SNRPN promoter is the primary diagnostic first-line test for both PWS and AS, distinguishing paternal (unmethylated) from maternal (methylated) alleles.

Cancer Epigenetic Biomarkers in Molecular Pathology

In oncology, promoter CpG island hypermethylation of tumor suppressor genes leads to transcriptional silencing:

• MGMT Promoter Hypermethylation (Glioblastoma): The $O^6$-methylguanine-DNA methyltransferase (MGMT) gene encodes a DNA repair protein that removes alkyl groups added by chemotherapy. Hypermethylation of the MGMT promoter silences the gene, disabling DNA repair and predicting a superior therapeutic response to alkylating chemotherapy (temozolomide) in glioblastoma patients.
• MLH1 Promoter Hypermethylation (Colorectal Carcinoma): Mismatch repair gene MLH1 silencing by promoter hypermethylation causes high microsatellite instability (MSI-H) in ~15% of sporadic colorectal cancers. Testing for MLH1 hypermethylation and the BRAF V600E mutation differentiates sporadic MSI-H tumors from hereditary Lynch syndrome (which lacks MLH1 promoter hypermethylation and lacks BRAF mutations).

The Gold Standard: Sodium Bisulfite Conversion Chemistry

Genomic DNA + Sodium Bisulfite (pH 5.0, 50-55°C)
    |
    +---> Unmethylated Cytosine  ---(Sulfonation/Deamination/Desulfonation)--->  Uracil  ---> Amplified as THYMINE in PCR
    |
    +---> 5-Methylcytosine (5-mC) ----------------(Protected)----------------->  5-mC   ---> Amplified as CYTOSINE in PCR

The clinical laboratory gold standard for mapping DNA methylation is Sodium Bisulfite Conversion:

1. Chemical Mechanism: Under acidic conditions ($\text{pH} \approx 5.0$), unmethylated cytosines undergo sulfonation at C6, hydrolytic deamination at C4 to form uracil sulfonate, and subsequent alkaline desulfonation to yield Uracil.
2. Protection of 5-mC: The methyl group on carbon-5 of 5-methylcytosine sterically and electronically protects the ring from sulfonation, leaving 5-mC completely unmodified as cytosine.
3. PCR Readout: During downstream PCR amplification, DNA polymerase recognizes Uracil as Thymine (inserting Adenine in the opposite strand). Thus, after bisulfite conversion and PCR:
   • Unmethylated Cytosines appear as Thymines (T).
   • Methylated Cytosines (5-mC) appear as Cytosines (C).
4. Methylation-Specific PCR (MSP): Uses two distinct primer sets:
   • M Primer Set: Specifically anneals to methylated bisulfite-converted sequence (contains C complementary to unconverted 5-mC).
   • U Primer Set: Specifically anneals to unmethylated bisulfite-converted sequence (contains T complementary to converted uracil).